Quality/GMPs

A review of key industry shifts and promises for the future.

The authors discuss a new, rapid immunoassay for the detection of biomarkers.

Formulators and developers are at the heart of the industry's basic premise-they are saving lives.

Industry experts discuss significant achievements. Plus: What's in store for the future.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has welcomed the launch of a EUR 223.7-million ($276.5 million) program to tackle antimicrobial resistance and speed up the development of new antibiotics.

ICH Q11, the anticipated guideline from the International Conference on Harmonization, titled Development and Manufacture of Drug Substances, has achieved international consensus. Q11 has been one of the fastest guidelines to move through the ICH harmonization process.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has formally adopted a memorandum of understanding (MoU) with key partners for a harmonised, European system for medicines verification.

The UK's Medicines and Healthcare products Regulatory Agency has launched a new anticounterfeiting strategy with the aim of curbing the occurrence of falsified medicines in the county's supply chain.

Manufacturers seek clear path to develop safe-use approaches for more risky OTC therapies.

Future sponsor-contract provider relationships will require more integration.

Featuring expert insights from GSK Biologicals, Baxter Pharmaceutical Solutions, GEA Pharma Systems, and more.

How to handle and respond to a consent decree.

The European Commission is offering a EUR 2-million ($2.64 million) inducement prize to encourage innovation in the area of cold-chain logistics and vaccine stability.

Better news about the global economy buoys life-sciences funding.

FDA has created a dedicated cadre of foreign drug investigators and established permanent offices worldwide.

Soaring opioid use creates challenges for new drug development and supply-chain control.

A closer look at elastomer changeout times provides one example of using industry knowledge to improve operations and cost.

This month, we rewind to an article titled "Good Manufacturing Practices Training."

The confluence of science, technology, and regulation will provide our industry with the guidance to move forward.

The author describes an equation that can be used to define the Quality relationship between a contract manufacturing organization and a client, including how to factor in both party's needs and regulatory commitments.

Outsourcing in the pharmaceutical industry, until recently, has been largely confined to commercial manufacturing, packaging, and support for clinical trials.

Challenges of vaccine development include regulatory, technical, and manufacturing hurdles in translating a vaccine candidate into a commercial product.

Because of the complexity of the manufacturing processes for biologics, transfer of these processes to a contract manufacturer presents challenges.

Does global development have to entail multiple comparability studies?

Social media use raises questions about applying old standards to new information technology.

Key business considerations when developing biosimilar products virtually.

Has the long-awaited guidance answered all of the industry's questions?

The authors compare the exposure risk from viable particles from the air supply in four well-established aseptic filling technologies.

Focusing on how risk affects the entire organization can improve the business bottom line.

Key technical considerations when developing a clinical project in the biotech world.